Alzamend Neuro, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc. (ALZN) on June 22, 2021, reporting events occurring on June 17, 2021. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Tampa, Florida. The filing primarily addresses the execution of a new employment agreement with the Chief Executive Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
Material Changes and Executive Compensation
On June 17, 2021, the Company entered into an employment agreement with Stephan Jackman, extending his role as Chief Executive Officer through July 1, 2024. Key terms include:
- Base Salary: $300,000 per annum.
- Performance Bonus: Eligible for cash and/or equity bonuses based on objectives determined by the Board, subject to verification by an independent registered public accounting firm.
- Equity Grants:
- 5,000,000 options at $1.00/share (previously granted): 3,000,000 vest ratably over 48 months from November 16, 2018; 1,000,000 vest upon FDA NDA approval for LiProSal by November 1, 2022; 1,000,000 vest upon FDA NDA approval for CAO22W by November 1, 2022.
- 2,000,000 options at $1.50/share: Vest upon satisfaction of mutually agreed performance criteria.
- Clawback Provisions: Bonuses and stock-based compensation are subject to clawback in the event of a financial restatement during employment or for two years post-termination.
- Termination Benefits: In the event of termination (excluding death, disability, cause, or resignation without good reason), Mr. Jackman is entitled to 12 months of base salary, a prorated performance bonus, and immediate vesting of all options exercisable for 12 months post-termination.
Guidance, Outlook, and Risks
The filing does not contain financial guidance or general outlook commentary. However, it highlights specific operational milestones tied to executive compensation: the approval of New Drug Applications (NDA) for LiProSal and CAO22W by the U.S. Food and Drug Administration (FDA) by November 1, 2022. Failure to meet these milestones would impact the vesting of specific equity awards.
Investor Verification Checklist
- Verify the current status of the FDA New Drug Applications for LiProSal and CAO22W to assess the likelihood of the November 1, 2022 vesting milestones.
- Review the full text of the Executive Employment Agreement (Exhibit 10.1) for detailed performance criteria regarding the $1.50 options and performance bonuses.
- Confirm the Company's cash position to evaluate its ability to fund the potential 12-month separation payment and base salary obligations.
- Monitor future filings for any restatements of financial results that could trigger the clawback provisions.